Noemie Leblay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Noemie Leblay has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Nizar Jacques Bahlis
Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
46 shared publications - David Jung
Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
43 shared publications - Lawrence H. Boise
Emory University
43 shared publications - Sungwoo Ahn
Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
43 shared publications - Benjamin Gabriel Barwick
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
42 shared publications - Jonathan J. Keats
Translational Genomics Research Institute
42 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 15 January 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (3) , 964-977
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma
Tumor-intrinsic adaptations with emerging resistant clones following T cell-targeted immunotherapies pose a major barrier to durable remissions in multiple myeloma. Through integrated genomic, transcriptomic and epigenomic interrogation of clonal plasma cells, we observed antigenic drift in 68.4% of relapsed cases following anti-GPRC5D T cell-engager (TCE) therapy (n = 21). These escape events were driven by three distinct mutational mechanisms involving (1) focal to large biallelic deletions at the GPRC5D gene locus; (2) monoallelic deletion coupled with GPRC5D single-nucleotide variants or insertions/deletions (indels) on the remaining allele; as well as (3) epigenetic GPRC5D promoter/enhancer silencing. Beyond biallelic deletions resulting in complete antigenic loss, we demonstrate that GPRC5D single-nucleotide variants and indels mutate anti-GPRC5D TCE-binding epitopes or more commonly affect G-protein-coupled receptor family conserved motifs critical for protein membrane trafficking resulting in endoplasmic reticulum GPRC5D trapping. Multiple subclones bearing distinct genomic alterations at GPRC5D locus co-emerged within individual cases, depicting their convergent evolutionary trajectories. Of note, anti-GPRC5D TCEs with varying epitope specificity, affinity and valency differentially targeted mutant subclones, underscoring their nonredundant functional roles in overcoming resistance.
- 15 January 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (3) , 964-977
Top Cited PapersOpen AccessMultimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma
Tumor-intrinsic adaptations with emerging resistant clones following T cell-targeted immunotherapies pose a major barrier to durable remissions in multiple myeloma. Through integrated genomic, transcriptomic and epigenomic interrogation of clonal plasma cells, we observed antigenic drift in 68.4% of relapsed cases following anti-GPRC5D T cell-engager (TCE) therapy (n = 21). These escape events were driven by three distinct mutational mechanisms involving (1) focal to large biallelic deletions at the GPRC5D gene locus; (2) monoallelic deletion coupled with GPRC5D single-nucleotide variants or insertions/deletions (indels) on the remaining allele; as well as (3) epigenetic GPRC5D promoter/enhancer silencing. Beyond biallelic deletions resulting in complete antigenic loss, we demonstrate that GPRC5D single-nucleotide variants and indels mutate anti-GPRC5D TCE-binding epitopes or more commonly affect G-protein-coupled receptor family conserved motifs critical for protein membrane trafficking resulting in endoplasmic reticulum GPRC5D trapping. Multiple subclones bearing distinct genomic alterations at GPRC5D locus co-emerged within individual cases, depicting their convergent evolutionary trajectories. Of note, anti-GPRC5D TCEs with varying epitope specificity, affinity and valency differentially targeted mutant subclones, underscoring their nonredundant functional roles in overcoming resistance.
- Top Cited PapersOpen Access
- 19 December 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (25) , 2637-2651
Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma
Adoptive T-cell therapy is a promising therapy for multiple myeloma (MM), but its efficacy hinges on understanding the relevant biologic and predictive markers of response. B-cell maturation antigen (BCMA) is a key target antigen in MM with active development of multiple anti-BCMA T-cell engagers (TCEs) and chimeric antigen receptor T-cell therapies. The regulation of surface BCMA expression by MM cells, which leads to shedding of soluble BCMA (sBCMA), has triggered debate about the significance of sBCMA as a predictive marker and its potential impact on treatment outcomes. To address this, we leveraged whole-genome sequencing and in vitro assays to demonstrate that sBCMA may independently predict primary refractoriness to anti-BCMA therapies. In addition to sBCMA, tumor burden and surface BCMA antigen density collectively influenced the anti-BCMA TCE cytotoxic efficacy. Correlative analyses of 163 patients treated with the anti-BCMA TCE teclistamab validated and further underscored the association between elevated baseline sBCMA (>400 ng/mL) and refractoriness. Importantly, increasing the TCE dose, using TCE against alternative targets (eg, GPRC5D), and gamma secretase inhibitors were able to overcome the high sBCMA levels. These findings highlight the importance of taking into account the baseline sBCMA levels, disease burden, and TCE dose intensity when administering anti-BCMA TCEs, thereby offering critical insights for optimizing therapeutic strategies to overcome specific high-risk features and primary anti-BCMA TCE refractoriness.
- 19 December 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (25) , 2637-2651
Top Cited PapersOpen AccessImpact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma
Adoptive T-cell therapy is a promising therapy for multiple myeloma (MM), but its efficacy hinges on understanding the relevant biologic and predictive markers of response. B-cell maturation antigen (BCMA) is a key target antigen in MM with active development of multiple anti-BCMA T-cell engagers (TCEs) and chimeric antigen receptor T-cell therapies. The regulation of surface BCMA expression by MM cells, which leads to shedding of soluble BCMA (sBCMA), has triggered debate about the significance of sBCMA as a predictive marker and its potential impact on treatment outcomes. To address this, we leveraged whole-genome sequencing and in vitro assays to demonstrate that sBCMA may independently predict primary refractoriness to anti-BCMA therapies. In addition to sBCMA, tumor burden and surface BCMA antigen density collectively influenced the anti-BCMA TCE cytotoxic efficacy. Correlative analyses of 163 patients treated with the anti-BCMA TCE teclistamab validated and further underscored the association between elevated baseline sBCMA (>400 ng/mL) and refractoriness. Importantly, increasing the TCE dose, using TCE against alternative targets (eg, GPRC5D), and gamma secretase inhibitors were able to overcome the high sBCMA levels. These findings highlight the importance of taking into account the baseline sBCMA levels, disease burden, and TCE dose intensity when administering anti-BCMA TCEs, thereby offering critical insights for optimizing therapeutic strategies to overcome specific high-risk features and primary anti-BCMA TCE refractoriness.
- 3 July 2024
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 21 (8) , 590-609
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
A better understanding of the roles of the adaptive and innate immune systems in the oncogenesis of cancers including multiple myeloma (MM) has led to the development of novel immune-based therapies. B cell maturation antigen (BCMA), G protein-coupled receptor family C group 5 member D (GPRC5D) and Fc receptor-like protein 5 (FcRL5, also known as FcRH5) are cell-surface transmembrane proteins expressed by plasma cells, and have been identified as prominent immunotherapeutic targets in MM, with promising activity demonstrated in patients with heavily pretreated relapsed and/or refractory disease. Indeed, since 2020, antibody–drug conjugates, bispecific T cell engagers and autologous chimeric antigen receptor T cells targeting BCMA or GPRC5D have been approved for the treatment of relapsed and/or refractory MM. However, responses to these therapies are not universal, and acquired resistance invariably occurs. In this Review, we discuss the various immunotherapeutic approaches targeting BCMA, GPRC5D and FcRL5 that are currently either available or in clinical development for patients with MM. We also review the mechanisms underlying resistance to such therapies, and discuss potential strategies to overcome these mechanisms and improve patient outcomes.
- 3 July 2024
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 21 (8) , 590-609
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
A better understanding of the roles of the adaptive and innate immune systems in the oncogenesis of cancers including multiple myeloma (MM) has led to the development of novel immune-based therapies. B cell maturation antigen (BCMA), G protein-coupled receptor family C group 5 member D (GPRC5D) and Fc receptor-like protein 5 (FcRL5, also known as FcRH5) are cell-surface transmembrane proteins expressed by plasma cells, and have been identified as prominent immunotherapeutic targets in MM, with promising activity demonstrated in patients with heavily pretreated relapsed and/or refractory disease. Indeed, since 2020, antibody–drug conjugates, bispecific T cell engagers and autologous chimeric antigen receptor T cells targeting BCMA or GPRC5D have been approved for the treatment of relapsed and/or refractory MM. However, responses to these therapies are not universal, and acquired resistance invariably occurs. In this Review, we discuss the various immunotherapeutic approaches targeting BCMA, GPRC5D and FcRL5 that are currently either available or in clinical development for patients with MM. We also review the mechanisms underlying resistance to such therapies, and discuss potential strategies to overcome these mechanisms and improve patient outcomes.
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
Differentially expressed genes and GSEA in OPM2 cells following shRNA knockdown of IKZF3.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
Differentially expressed genes and GSEA in OPM2 cells following shRNA knockdown of IKZF3.
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
Univariate and multi-variate analysis of ETV4 expression in the CoMMpass NDMM patients treated with IMiD as part of front-line therapy (N=567).
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
Univariate and multi-variate analysis of ETV4 expression in the CoMMpass NDMM patients treated with IMiD as part of front-line therapy (N=567).
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 5 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
ETV4 ChIP-seq binding sites in RPMI8226 cells.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 5 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
ETV4 ChIP-seq binding sites in RPMI8226 cells.
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 4 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
JASPAR transcription factor binding motifs enriched in IKZF1-bound regions in RPMI8226 cells where the cognate transcription factor was expressed at greater than 1 FPKM and the FDR enrichment significance P ≤ 10e-10.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 4 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
JASPAR transcription factor binding motifs enriched in IKZF1-bound regions in RPMI8226 cells where the cognate transcription factor was expressed at greater than 1 FPKM and the FDR enrichment significance P ≤ 10e-10.
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 6 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
ETV4 mRNA data and outcome from the POLLUX and MM-010 trials.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 6 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
ETV4 mRNA data and outcome from the POLLUX and MM-010 trials.
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 6 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
ETV4 mRNA data and outcome from the POLLUX and MM-010 trials.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 6 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
ETV4 mRNA data and outcome from the POLLUX and MM-010 trials.
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 7 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
Genes whose expression are associated with ETV4 in NDMM and in RRMM patients enrolled in the CoMMpass study.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 7 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
Genes whose expression are associated with ETV4 in NDMM and in RRMM patients enrolled in the CoMMpass study.